Ani Pharmaceuticals (ANIP) Short-Term Debt repayments (2020 - 2025)
Ani Pharmaceuticals (ANIP) has disclosed Short-Term Debt repayments for 6 consecutive years, with -$6.1 million as the latest value for Q4 2025.
- Quarterly Short-Term Debt repayments fell 102.09% to -$6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $297.1 million through Sep 2025, up 39712.4% year-over-year, with the annual reading at $292.5 million for FY2024, N/A changed from the prior year.
- Short-Term Debt repayments hit -$6.1 million in Q4 2025 for Ani Pharmaceuticals, down from $2.0 million in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of $291.0 million in Q4 2024 to a low of -$6.1 million in Q4 2025.
- Historically, Short-Term Debt repayments has averaged $30.6 million across 5 years, with a median of $1.4 million in 2022.
- Biggest five-year swings in Short-Term Debt repayments: soared 13033.33% in 2024 and later plummeted 102.09% in 2025.
- Year by year, Short-Term Debt repayments stood at $192.1 million in 2021, then plummeted by 101.17% to -$2.2 million in 2022, then changed by 0.0% to -$2.2 million in 2023, then skyrocketed by 13033.33% to $291.0 million in 2024, then tumbled by 102.09% to -$6.1 million in 2025.
- Business Quant data shows Short-Term Debt repayments for ANIP at -$6.1 million in Q4 2025, $2.0 million in Q3 2025, and $2.0 million in Q2 2025.